Dr. Nancy Reid, MHA, DHSc, PA-C, DFAAPA
Although studies have shown that individuals with Type 2 diabetes mellitus (T2DM) are at a higher risk to develop colorectal cancer, definitive links between the two diseases remain inconclusive. Therefore, much research has been focused on into discovering the common factor that ultimately leads to higher morbidity and mortality rates when these two diseases concurrently affect an individual. However, there have been studies that investigate the protective roles of T2DM medical treatment in minimizing the development of malignancy. Since patients with T2DM begin to require insulin sensitizing therapy when there is significant decline in endogenous insulin production, the aim of this review is to discuss if metformin therapy leads to reduced risk, development, and progression of colorectal cancer in T2DM patients.
Frizell, Carl A.
"The Emerging Link between Metformin Therapy for Type 2 Diabetes Mellitus and Colorectal Cancer,"
Lynchburg Journal of Medical Science: Vol. 1
, Article 19.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol1/iss4/19
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.